Quarterly report pursuant to Section 13 or 15(d)

Subsequent events (Details)

v3.8.0.1
Subsequent events (Details)
Apr. 28, 2017
USD ($)
$ / shares
shares
Apr. 17, 2017
USD ($)
Apr. 13, 2017
USD ($)
Subsequent events Details      
Mentor entered into an agreement to provide funding to offset costs of the application     $ 40,000
Shareholders hold Series B Warrants   $ 3,000,000  
Shareholders hold Series B Warrants will receive per warrant redemption payment   0.1  
Company invested an additional in Electrum by purchase of a second promissory note $ 100,000    
Purchase of a second promissory note in principal face amount $ 100,000    
Electrum with interest per annum compounded monthly 10.00%    
Monthly principal and interest payments to the Company $ 2,290    
Fixed equity conversion rate per share | $ / shares $ 164    
Electrum to allow interest only payments to continue until Mentor determines $ 898    
Monthly payments of principal and interest per month 2,124    
Company increased the total amount invested in G Farma from $500,000 600,000    
Increasing the principal face amount of the working capital note by $100,000 to 480,000    
Monthly principal and interest payments on the working capital note will increase from $3,505 per month to 4,427    
Payments for services provided under the Consulting Agreement will increase from 1,400 per month to $ 1,680    
Farma also purchased an additional shares of Company Common Stock | shares 66,667    
Farma also purchased an additional shares of Company Common Stock at per share | $ / shares $ 1.5    
Farma also purchased an additional shares of Company Common Stock for an additional payable | shares 100,000    
Company received from warrant redemptions $ 98,358